Quanterix reports Q3 EPS (21c), consensus (37c)

Reports Q3 revenue $31.3M, consensus $27.6M. cash were $330.4 million as of September 30, 2023, as compared to $332.2 million as of June 30, 2023. “We’re on track to achieve the six-quarter transformation plan we laid out by year end,” said Masoud Toloue, CEO of Quanterix. “This will not only yield highly scaled production lines but serve as the foundation for an accelerated innovation rate going into next year. Last month’s launch of our LucentAD p-Tau 217 blood-based test puts us in a leading position to address broad-based, non-invasive patient testing for Alzheimer’s disease. We expect a faster release pace of pioneering, high sensitivity Simoa products going into 2024.”